Significant EBITDA Growth
Adjusted EBITDA reached $222 million, marking an $83 million or 60% year-over-year increase, driven by strong cellulose specialty pricing and volumes.
Improved Free Cash Flow
2024 adjusted free cash flow stood at $128 million, an improvement of $75 million or 142% from 2023.
Debt Reduction Achievements
Net secured debt decreased by $73 million, and the net secured leverage ratio improved to 2.7 times covenant EBITDA.
Strategic Capital Investments
Invested $33 million in high-return projects, including plant efficiency enhancements and ERP upgrades.
Biomaterial Strategy Progress
Advancing biomaterial projects with potential to generate $55 million in EBITDA once full production is achieved.